Good evening :)
$
₹
C

Clinuvel Pharmaceuticals Ltd ADR

CUVL

PINK
C

Clinuvel Pharmaceuticals Ltd ADR

CUVL

PINK
$4.951.59% (-0.08)
$
₹
$4.951.59% (-0.08)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $258.5M the stock is ranked 3947

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

11.37
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.51
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.45
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

36.07%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.96%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

—

Earnings Growth

—

Rev. Growth

+0.47%

See Detailed Forecast

Company Profile

Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.45
80.45
1Y Return
24.54%
24.54%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.22
27.22
1Y Return
49.15%
49.15%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.41%
29.41%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.37
30.37
1Y Return
25.49%
25.49%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
654.67%
654.67%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 0.47% growth, versus a trailing 3-year CAGR of 6.28%.

2026
Current$94.02Baseline
Forecast for Jun 2027
High$98.7+4.97%
Average$94.46+0.47%
Low$89.8-4.49%

All values in $ Million

20222023202420252026202765.7278.3288.1795.0194.02Low-4.49%Average+0.47%High+4.97%
2026
Current$94.02Baseline
Forecast for Jun 2027
High$98.7+4.97%
Average$94.46+0.47%
Low$89.8-4.49%

All values in $ Million

Financials

Financials

Income

Balance Sheet

Cash Flow

Q2 2025
Q2 2026
Revenue
Net Income
Financial YearQ2 2025Q2 2026
Total Revenue--
Net Income--
Net Profit Margin--
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Clinuvel Pharmaceuticals Ltd ADR 11.371.51-
AbbVie Inc80.4550.450.54
Amgen Inc27.2218.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CUVL with any stock or ETF
Compare CUVL with any stock or ETF
Comparing from
CUVL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Clinuvel Pharmaceuticals Ltd ADR (CUVL) share price today is $4.95 as of October 23, 2026 at 10:22 PM IST. The stock touched a day high of $5.01 and a day low of $4.95.

  2. Clinuvel Pharmaceuticals Ltd ADR stock trades on PINK under the ticker symbol CUVL.

  3. Clinuvel Pharmaceuticals Ltd ADR's market capitalization is $258.49M as of October 23, 2026 at 10:22 PM IST.

  4. Clinuvel Pharmaceuticals Ltd ADR's price-to-earnings (P/E) ratio is 11.37 as of October 23, 2026.

  5. Clinuvel Pharmaceuticals Ltd ADR's price-to-book (P/B) ratio is 1.51 as of October 23, 2026.

  6. Yes, Clinuvel Pharmaceuticals Ltd ADR pays a dividend, with a current dividend yield of 0.96%.

  7. Yes, You can buy Clinuvel Pharmaceuticals Ltd ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Clinuvel Pharmaceuticals Ltd ADR shares in three steps: 1. Search Clinuvel Pharmaceuticals Ltd ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Clinuvel Pharmaceuticals Ltd ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Clinuvel Pharmaceuticals Ltd ADR (CUVL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.0202 shares at the current price of $4.95.

Loading...